Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | CDC7 | O00311 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 2/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9918751 | 0.73 | CYP1A2 (0.42) | ALDH1A1LMNAKMT2ACYP3A4SMN1; SMN2 | |
| SCHEMBL9918796 | 0.71 | DGAT1 (0.38) | ALDH1A1KMT2AMAPTCDC7PARP1 | |
| SCHEMBL404648 | 0.67 | MAPT (0.54) | ALDH1A1LMNAKMT2ACYP3A4SMN1; SMN2 | |
| SCHEMBL23011996 | 0.66 | LMNA (0.49) | ALDH1A1LMNAKMT2ACYP3A4SMN1; SMN2 | |
| SCHEMBL3800705 | 0.66 | ALDH1A1 (0.49) | ALDH1A1LMNAKMT2ACYP3A4SMN1; SMN2 | |
| SCHEMBL590089 | 0.64 | TDP1 (0.56) | ALDH1A1LMNAKMT2ACYP3A4SMN1; SMN2 | |
| SCHEMBL13844206 | 0.64 | KMT2A (0.60) | ALDH1A1LMNAKMT2ACYP3A4SMN1; SMN2 | |
| SCHEMBL404749 | 0.64 | ATM (0.52) | ALDH1A1LMNAKMT2ACYP3A4SMN1; SMN2 | |
| SCHEMBL10271931 | 0.64 | ALDH1A1 (0.40) | ALDH1A1LMNAKMT2ACYP3A4SMN1; SMN2 | |
| SCHEMBL4485751 | 0.64 | KMT2A (0.60) | ALDH1A1LMNAKMT2ACYP3A4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012106448-A1 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-08-09 | — | — | WO | disclosed |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2011031554-A2 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | ALDH1A1 1507/4885LMNA 4638/4885KMT2A 628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.